Nicholas J. Vogelzang, MD
Medical Oncologist
Ovarian Cancer Pericardial Mesothelioma Pleural Mesothelioma Testicular Mesothelioma
Biological Therapy/Immunotherapy Chemotherapy Pain Management Targeted Therapy
Dr. Vogelzang is a well known specialist in the field of oncology, specifically mesothelioma, and has been practicing as a medical oncologist at the Comprehensive Cancer Centers of Nevada. He graduated from the University of Chicago Medical School in Illinois and moved on to the Rush Presbyterian St. Luke’s Medical Center, where he completed his residency. The University of Minnesota is where Dr. Nicholas Vogelzang completed his fellowship. With two board certifications, in internal medicine and medical oncology, Dr. Vogelzang is well respected for his expertise regarding the diagnosis and treatment of mesothelioma, a very aggressive type of cancer. In latter part of his career, Dr. Vogelzang moved into the field of research and clinical trials, with important advances coming from this.
University of Illinois, Chicago, IL - 1974
Medical School
Rush Presbyterian St. Luke’s Medical Center, Chicago, IL
Residency
University of Minnesota, Minneapolis, MN
Fellowship
American Board of Internal Medicine
American Board of Internal Medicine - Oncology
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
Cora Sternberg, Andrew Armstrong, Roberto Pili, Siobhan Ng, Robert Huddart, Neeraj Agarwal, Denis Khvorostenko, Olexiy Lyulko, Arija Brize, Nicholas Vogelzang, Rémy Delva, Mihai Harza, Anastasios Thanos, Nicholas James, Patrick Werbrouck, Martin Bögemann, Thomas Hutson, Piotr Milecki, Simon Chowdhury, Enrique Gallardo, Gilberto Schwartsmann, Jean-Christophe Pouget, Frédérique Baton, Thore Nederman, Helen Tuvesson and Michael Carducci⇑
See more >>Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospectiv...
Pal SK1, Signorovitch JE2, Reichmann WM3, Li N3, Koo V3, Liu Z4, Perez JR4, Vogelzang NJ5.
See more >>Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
Vogelzang NJ1, Pal SK2, Signorovitch JE3, Reichmann WM3, Li N3, Yang C3, Liu Z4, Perez JR4, Jonasch E5.
See more >>Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
Halabi S1, Kelly WK2, Ma H2, Zhou H2, Solomon NC2, Fizazi K2, Tangen CM2, Rosenthal M2, Petrylak DP2, Hussain M2, Vogelzang NJ2, Thompson IM2, Chi KN2, de Bono J2, Armstrong AJ2, Eisenberger MA2, Fandi A2, Li S2, Araujo JC2, Logothetis CJ2, Quinn DI2, Morris MJ2, Higano CS2, Tannock IF2, Small EJ2.
See more >>American Association for Cancer Research
American College of Physicians
American Society of Clinical Oncology
European Society for Medical Oncology
International Association for the Study of Lung Cancer
Mesothelioma Applied Research Foundation
June 04, 2015
by Luann G.
Wait Time
Staff
Helpfulness
Knowledge
“Dr. Vogelzang is the best for bladder cancer. The office is kind of busy, but is worth waiting. ”
June 14, 2012
by Olden J
Wait Time
Staff
Helpfulness
Knowledge
“I was honored to meet doctor Vogelzang and talk to him. I had a rare form of cancer and he explained me more about my case. ”